Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662124 | 0.85 | THRB (0.39) | MCL1BCL2THRB | |
| SCHEMBL2252786 | 0.83 | MCL1 (0.33) | MCL1BCL2MEN1KMT2ATDP1 | |
| SCHEMBL31352403 | 0.82 | CRBN (0.39) | MCL1BCL2 | |
| SCHEMBL29224511 | 0.82 | THRB (0.47) | MCL1BCL2THRB | |
| SCHEMBL29224228 | 0.82 | THRB (0.47) | MCL1BCL2THRB | |
| SCHEMBL15069311 | 0.80 | THRB (0.34) | MCL1THRB | |
| SCHEMBL2988471 | 0.78 | DPP4 (0.33) | — | |
| SCHEMBL428708 | 0.78 | — | — | |
| SCHEMBL31623264 | 0.78 | HSD11B1 (0.33) | MCL1 | |
| SCHEMBL9913516 | 0.77 | MCL1 (0.31) | MCL1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094947-A | PARP1 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2025073554-A2 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| WO-2024153226-A1 | PYRAZOLE-FUSED CYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| EP-3645516-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Janssen Pharmaceutica NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| WO-2013130890-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013130890-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | AMGEN INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | AMGEN INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | AMGEN INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8420629-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-8158616-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-03-29 | — | — | US | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | PDE10A, PDE1B, PDE9A | MCL1 1353/4885BCL2 1215/4885THRB 169/4885 |
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | MCL1 33/4885BCL2 492/4885THRB 1348/4885 |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | MCL1 887/4885BCL2 685/4885THRB 1323/4885 |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | MCL1 33/4885BCL2 492/4885THRB 1348/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | MCL1 1638/4885BCL2 1131/4885THRB 615/4885 |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | MCL1 33/4885BCL2 492/4885THRB 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.